Trial Profile
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms IMAAGEN
- Sponsors Janssen Biotech
- 25 Aug 2021 Results of a meta-analysis assessing efficacy and safety of treatments for nonmetastatic castration-resistant prostate cancer using patient level data from two studies (IMAAGEN, STRIVE) and aggregate data from other eligible nmCRPC trials presented at the 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 20 May 2021 Planned End Date changed from 31 Jul 2022 to 31 Jul 2024.
- 20 May 2021 Results of meta analysis of 6 trials including STRIVE and IMAAGEN presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research